Tweet
Matinas BioPharma (NYSEAMERICAN:MTNB) had its target price cut by Maxim Group from $3.00 to $2.00 in a research note released on Monday morning. They currently have a buy rating on the stock.
Shares of NYSEAMERICAN MTNB opened at $0.38 on Monday. Matinas BioPharma has a twelve month low of $0.32 and a twelve month high of $1.60. Get Matinas BioPharma alerts:
Matinas BioPharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Friday, August 10th. The company reported ($0.04) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.04). Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. The company had revenue of $0.09 million during the quarter.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in Matinas BioPharma by 3.4% during the 4th quarter. BlackRock Inc. now owns 2,530,508 shares of the company's stock valued at $2,935,000 after buying an additional 84,226 shares during the last quarter. Royal Bank of Canada raised its stake in Matinas BioPharma by 134.5% during the 1st quarter. Royal Bank of Canada now owns 784,154 shares of the company's stock valued at $599,000 after buying an additional 449,761 shares during the last quarter. Paloma Partners Management Co raised its stake in Matinas BioPharma by 1,724.7% during the 2nd quarter. Paloma Partners Management Co now owns 317,499 shares of the company's stock valued at $138,000 after buying an additional 300,099 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in Matinas BioPharma by 184.8% during the 4th quarter. Deutsche Bank AG now owns 148,042 shares of the company's stock valued at $171,000 after buying an additional 96,054 shares during the last quarter.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable